TB-500

Mechanism of action

TB-500 is the commercial designation for a synthetic peptide derived from residues 17 to 23 of thymosin beta-4 (Tβ4), encompassing the sequence Leu-Lys-Lys-Thr-Glu-Thr-Gln. This heptapeptide contains the principal G-actin-binding motif of the full 43-amino-acid parent protein — specifically the LKKTET sequence that interacts with subdomain 1 of monomeric actin. By binding and sequestering cytoplasmic G-actin, TB-500 influences the dynamic equilibrium between monomeric and filamentous actin (the G-F actin ratio), which in turn governs cytoskeletal organisation, cell polarity, and migratory capacity. This mechanism positions TB-500 as a promoter of directed cell migration — a prerequisite for wound closure, tendon-fibroblast infiltration, and vascular ingrowth. Upstream of cytoskeletal effects, TB-500 is reported to upregulate vascular endothelial growth factor (VEGF) expression in several cell-culture and tissue models. Increased VEGF promotes angiogenesis and endothelial proliferation, contributing to the neovascularisation that underpins the accelerated wound closure observed in murine full-thickness wound experiments (Malinda K.M. et al., FASEB J, 1999; 2003). Laminin-5, a basement-membrane glycoprotein that anchors epithelial cells and promotes keratinocyte migration, is also reported to be upregulated in TB-500-treated wound beds. Anti-inflammatory activity has been attributed to suppression of the NF-κB signalling pathway in inflammatory-cell populations. Reduced nuclear translocation of NF-κB p65 has been observed in lipopolysaccharide-stimulated macrophages exposed to full-length Tβ4 and its central fragment, with consequent reductions in TNF-α, IL-1β, and IL-6 secretion. This anti-inflammatory profile complements rather than replaces the reparative effects: dampening the destructive early inflammatory phase accelerates the transition to proliferative healing. In cardiac tissue, full-length Tβ4 has been demonstrated to mobilise dormant epicardial progenitor cells following myocardial ischaemia (Smart N. et al., Nature, 2007; PMID 17554319). Whether the shorter TB-500 fragment recapitulates this progenitor-mobilisation effect is not clearly established; most cardiac-regeneration research uses the full-length protein, and researchers should interpret marketed TB-500 cardiac claims with appropriate caution. Batch identity is a critical interpretive variable for TB-500 research. Commercial preparations vary considerably in peptide length and purity. Some preparations contain the full-length 43-amino-acid Tβ4 molecule, others the LKKTETQ heptapeptide, and yet others are mixtures. Independent mass-spectrometry verification is strongly recommended before attributing experimental outcomes to a specific molecular species.

The seven-amino-acid LKKTETQ actin-binding motif of thymosin beta-4 retains the full endothelial cell-migration activity of the 43-amino-acid parent protein, providing the mechanistic basis for TB-500 as a fragment-based research compound.

— Notable finding

Research history

Thymosin beta-4 was originally isolated from calf thymus tissue in 1981 by Allan Goldstein and colleagues at the National Institutes of Health, who characterised it as a thymic hormone involved in T-lymphocyte maturation. Subsequent biochemical studies in the 1990s revealed that the protein is not thymus-specific at all but is instead one of the most abundantly expressed intracellular proteins in mammalian cells — essentially wherever cytoskeletal dynamics are required, Tβ4 is present. This reframing from thymic hormone to general cytoskeletal-regulator was foundational to the modern regenerative-medicine framing of the Tβ4 family. The discovery that the LKKTET motif within Tβ4 was the minimal sequence necessary for actin binding was made during structure-function studies in the early-to-mid 1990s and was foundational to the concept of fragment-based peptide therapy. Truncation and alanine-scanning experiments confirmed that the shorter fragment retained substantial actin-modulating activity, motivating pharmaceutical development of both the full-length protein and the shorter research-chemical fragment along parallel tracks. The commercial designation 'TB-500' entered the research-chemical marketplace in the early 2000s, originally in the context of equine veterinary medicine, where the compound was used by trainers in horse-racing to manage tendon injuries. This equine origin remains closely associated with the compound and explains some of the observational literature from veterinary sports medicine. Meanwhile, RegeneRx Biopharmaceuticals advanced full-length recombinant Tβ4 (as RGN-352) into Phase I and II human trials for acute myocardial infarction and (as RGN-259 ophthalmic drops) for neurotrophic keratitis and dry-eye disease. These programmes established that human exposure to exogenous Tβ4 is generally safe in the short term and provided the first pharmacokinetic data for the full-length molecule in humans. Results in cardiac applications were mixed; the corneal application has produced the strongest clinical signals, with subsequent Phase III programmes progressing toward potential registration in ophthalmology contexts. Across the 2010s and 2020s, TB-500 has consolidated a substantial research-chemical-market presence in the sport-recovery and soft-tissue-repair space, particularly in strength-sport and endurance-training communities. Regulatory bodies including WADA and MHRA have progressively formalised their stance on the compound during this period, and enforcement in athletic populations subject to testing has clarified that TB-500 is treated as any other Tβ4 preparation under anti-doping rules.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Animal studies of both TB-500 (the fragment) and full-length thymosin beta-4 have reported a favourable acute toxicity profile across multiple species and routes of administration. Repeat-dose rodent studies at pharmacologically relevant doses have not revealed organ-level pathology on routine histopathology. Phase I human data from intravenous full-length Tβ4 (RGN-352, RegeneRx) confirmed no dose-limiting toxicities at doses tested; ophthalmic administration (RGN-259) has similarly been well-tolerated in Phase II and Phase III programmes. Common adverse events in the human-trial literature are limited to mild injection-site or topical-application reactions. The principal safety uncertainties for TB-500 specifically are batch composition and long-term immunogenicity. Preparations mislabelled as 'TB-500' may contain full-length Tβ4, the LKKTETQ fragment, or other thymosin-related peptides in varying proportions — this heterogeneity is a specific interpretive problem for both individual research and the aggregate literature, and it is one reason regulatory scrutiny of grey-market TB-500 supply is warranted. The immunogenic potential of repeated exogenous peptide administration — including possible anti-drug antibody formation — has not been systematically evaluated for the fragment. Pro-angiogenic activity, as with BPC-157, raises a theoretical consideration in neoplastic models where enhanced tumour vascularisation could plausibly accelerate growth. No tumour-promotion findings have been reported in the available literature, but the absence of dedicated oncology-safety studies means this concern remains theoretical rather than characterised. Contraindications and precautions on mechanistic grounds include: known malignancy or high-risk premalignant conditions (based on the pro-angiogenic mechanism); pregnancy and lactation (no safety data); active proliferative retinopathy or other pathological neovascularisation contexts. Interactions with concurrent anti-angiogenic medications (bevacizumab, ranibizumab, tyrosine-kinase inhibitors) are pharmacologically plausible but uncharacterised. For laboratory preparations, the standard quality caveats apply: HPLC purity ≥98%, mass-spectrometry identity confirmation, and endotoxin testing (LAL assay, <1 EU/mg) are the minimum requirements for any injectable research preparation. Sterility must be confirmed by standard membrane-filtration or direct-inoculation methods.

UK regulatory status

TB-500 is not licensed as a medicine by the MHRA and has no marketing authorisation in the United Kingdom. The compound has not undergone the clinical development required for product licensing; its use in the UK is strictly restricted to in-vitro and in-vivo pre-clinical laboratory research. Supplying, offering to supply, or advertising for supply of TB-500 to a member of the public engages the Human Medicines Regulations 2012 offences framework, and MHRA has jurisdiction over the promotion and supply of unlicensed medicines regardless of the compound's research-chemical framing. Advertising or promotional material referring to TB-500 for tendon injuries, sports recovery, or any therapeutic claim additionally engages Advertising Standards Authority (ASA) jurisdiction — the ASA has taken action against unlicensed peptide promotional material in analogous contexts. Suppliers positioning TB-500 as a research chemical while offering doses, protocols, or reconstitution guidance oriented to human use are at particular enforcement risk. For competitive athletes, TB-500 is prohibited under the World Anti-Doping Agency Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This prohibition applies both in-competition and out-of-competition and encompasses all forms and formulations of thymosin beta-4 and its fragments regardless of whether the material is labelled TB-500, thymosin beta-4, or by other commercial designation. Athletes who use TB-500 for any purpose risk anti-doping rule violations under strict liability. Veterinary use in the UK is likewise unlicensed for TB-500 specifically, although related research into thymosin-family proteins has been conducted in equine sports medicine contexts. Racing-industry authorities (British Horseracing Authority) treat TB-500 as a prohibited substance under racing rules regardless of the compound's research-chemical framing. For animal research under the Animals (Scientific Procedures) Act 1986 (ASPA), TB-500 work in vertebrates requires standard project and personal licences. No specific UK enforcement actions relating to TB-500 as a research chemical are recorded in the public domain to date.

Frequently asked questions